CompletedInterventional · Not applicableNCT05218967 ↗Virtual Reality as a Distraction Intervention for Pain Management During Office Laryngeal Procedures: Randomized Single Blinded Clinical TrialAnais RameauPIInterventionOther: Virtual Reality HeadsetDatesFeb 2022 – Aug 2022
CompletedInterventional · Phase 2NCT05224531 ↗A Phase 2, Prospective, Randomized, Open-label, Blinded Endpoint, Multicenter Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Exploratory Efficacy of 3 Doses of CS1 in Subjects With Pulmonary Arterial HypertensionEvelyn M. HornPIInterventionDrug: CS1 AdministrationDatesMay 2022 – Aug 2024SponsorCereno Scientific ABPulmonary Arterial Hypertension
CompletedInterventional · Phase 2NCT05238675 ↗A Randomised, Double-blind, Placebo-controlled, Parallel Group, Dose-finding Study Evaluating Efficacy, Safety and Tolerability of BI 1291583 qd Over at Least 24 Weeks in Patients With Bronchiectasis (AirleafTM)Michael S. NiedermanPIInterventionDrug: BI 1291583 · Drug: PlaceboDatesApr 2022 – May 2024SponsorBoehringer Ingelheim Pharmaceuticals, Inc. (USA)Bronchiectasis
CompletedInterventional · Phase 1NCT05245292 ↗An Open Label, Single Arm Study of the Safety and Antiretroviral Activity of Two Long-acting Broadly Neutralizing Antibodies Plus an IL-15 Superagonist in ART-treated Adults Living With HIV During Analytical Treatment InterruptionMarshall J. GlesbyPIInterventionDrug: 3BNC117-LS · Drug: 10-1074-LS · Drug: N803DatesDec 2022 – Dec 2025SponsorRockefeller UniversityHuman Immunodeficiency Virus
CompletedInterventional · Not applicableNCT05251363 ↗BIOTRONIK Conduction System Pacing With the Solia LeadChristopher F LiuPIInterventionDevice: Solia S leadDatesDec 2022 – Jan 2024· Results postedSponsorBIOTRONIK, Inc.BradycardiaAtrioventricular BlockLeft Bundle-Branch Block+1 more
CompletedInterventional · Phase 3NCT05279846 ↗A Multi-center, Double-blind, Randomized, Vehicle-controlled Study of Efficacy and Safety of Topical MOB015B in the Treatment of Mild to Moderate Distal Subungual Onychomycosis (DSO)Shari LipnerPIInterventionDrug: MOB015B · Drug: Vehicle (Placebo Comparator)DatesMay 2022 – Jan 2025 (est.)SponsorMoberg Pharma ABOnychomycosis
CompletedInterventional · Phase 2NCT05284617 ↗Exploratory Phase 2A, Double-blind, Placebo-Controlled, Dose Escalation Study to Determine the Safety, Tolerability, PD, and PK of HU6 for the Treatment of Subjects With Obese Heart Failure With Preserved Ejection Fraction (HFpEF)Parag GoyalPIInterventionDrug: HU6 · Drug: PlaceboDatesOct 2022 – May 2024SponsorRivus Pharmaceuticals, Inc.Heart Failure With Preserved Ejection Fraction
CompletedInterventional · Phase 3NCT05285982 ↗An Open-label Trial of the Long-term Safety and Tolerability of Nintedanib Per os, on Top of Standard of Care, Over at Least 3 Years, in Children and Adolescents With Clinically Significant Fibrosing Interstitial Lung Disease (InPedILD®-ON)Andrea HerasPIInterventionDrug: Nintedanib (Ofev®)DatesApr 2022 – Aug 2025· Results postedSponsorBoehringer Ingelheim Pharmaceuticals, Inc. (Germany)Lung Diseases, Interstitial
CompletedInterventional · Not applicableNCT05286879 ↗Addressing Risk Through Community Treatment for Infectious Disease and Opioid Use Disorder Now (ACTION) Among Justice-involved PopulationsCzarina Navos BehrendsPIInterventionBehavioral: Patient Navigator · Behavioral: Mobile Health UnitDatesMar 2022 – Jul 2025· Results postedSponsorNational Institute on Drug AbuseOpioid Use DisorderInfectious DiseaseRisk Reduction Behavior+3 more
CompletedInterventional · Not applicableNCT05288868 ↗The Effect of Simulation-based Training on Confidence and Competence in Obtaining Vitals in a Child With AutismKevin ChingPIInterventionOther: Educational Intervention: online didactic lecture and educational simulation activityDatesJun 2022 – May 2024SponsorWeill Medical College of Cornell UniversityAutism Spectrum Disorder
TerminatedInterventional · Phase 4NCT05293106 ↗Assessing the Hemostatic Efficacy of Pathogen Reduced Platelets in Children Undergoing Cardiopulmonary Bypass Surgery: A Pilot Clinical TrialMarianne Elizabeth NellisPIInterventionBiological: Platelet TransfusionDatesJul 2022 – Sep 2023· Results postedSponsorWeill Medical College of Cornell UniversityCardiopulmonary Bypass Surgery
CompletedInterventional · Phase 1NCT05293496 ↗A Phase 1/1b Dose Escalation and Cohort Expansion Study of MGC018 in Combination With Checkpoint Inhibitor in Participants With Advanced Solid TumorsCora SternbergPIInterventionBiological: vobramitamab duocarmazine · Biological: lorigerlimabDatesApr 2022 – Jun 2025SponsorMacroGenicsAdvanced Solid TumorCastration-Resistant Prostatic CancerMalignant Melanoma+4 more
CompletedInterventional · Not applicableNCT05293639 ↗Assessment of Safety and Effectiveness in Treatment Management of Atrial Fibrillation With the BWI IRE Ablation System (AdmIRE)Christopher F LiuPIInterventionDevice: Pulse Field AblationDatesApr 2022 – Dec 2023· Results postedSponsorBiosense Webster, Inc.Atrial Fibrillation
CompletedInterventional · Phase 2NCT05295875 ↗A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled and Parallel Group 48-Week Study to Evaluate the Efficacy and Safety of ALT-801 in the Treatment of Obesity (MOMENTUM Trial)Louis J AronnePIInterventionDrug: ALT-801 · Other: PlaceboDatesMar 2022 – Sep 2023SponsorAltimmune, Inc.Obesity/Overweight
CompletedInterventional · Phase 2NCT05309200 ↗A Multi-Center, Randomized, Placebo-Controlled, Double-Blind, Adaptive Dose-Ranging Study to Assess Safety and Efficacy of Intravenous OCE-205 in Adults Diagnosed With Cirrhosis With Ascites Who Have Developed Hepatorenal Syndrome-Acute Kidney Injury (HRS-AKI)Robert S. BrownPIInterventionDrug: OCE-205 · Drug: PlaceboDatesApr 2022 – Sep 2023SponsorOcelot Bio, Inc.CirrhosisAscitesHepatorenal Syndrome+1 more
CompletedInterventional · Phase 3NCT05321069 ↗A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Idiopathic Pulmonary Fibrosis (IPF)Robert J. KanerPIInterventionDrug: BI 1015550 · Drug: PlaceboDatesOct 2022 – Aug 2024· Results postedSponsorBoehringer Ingelheim Pharmaceuticals, Inc. (USA)Idiopathic Pulmonary Fibrosis
CompletedInterventional · Phase 3NCT05321082 ↗A Double Blind, Randomized, Placebo-controlled Trial Evaluating the Efficacy and Safety of BI 1015550 Over at Least 52 Weeks in Patients With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)Robert J. KanerPIInterventionDrug: BI 1015550 · Drug: PlaceboDatesNov 2022 – Dec 2024· Results postedSponsorBoehringer Ingelheim Pharmaceuticals, Inc. (USA)Lung Diseases, Interstitial
CompletedInterventional · Phase 2NCT05348785 ↗A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy and Safety of BIIB122 in Participants With Parkinson's DiseaseHarini SarvaPIInterventionDrug: BIIB122 · Drug: BIIB122-Matching PlaceboDatesApr 2022 – Mar 2026SponsorBiogen, Inc.Parkinson Disease
TerminatedInterventional · Phase 4NCT05369832 ↗A Phase 4, Prospective, Open-label Study of Ozanimod to Explore the Safety, Efficacy, Quality of Life, and Biomarker Response in Participants With Moderate to Severe Ulcerative Colitis in Clinical PracticeEllen J ScherlPIInterventionDrug: OzanimodDatesDec 2022 – Jan 2025· Results postedSponsorBristol-Myers Squibb CompanyColitis, Ulcerative
TerminatedInterventional · Phase 2NCT05370885 ↗Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study of VE202 in Patients With Mild-to-Moderate Ulcerative ColitisDana Jeremy LukinPIInterventionBiological: VE202 · Drug: Vancomycin Oral Capsule · Other: VE202 Placebo · Other: Vancomycin PlaceboDatesMay 2023 – Aug 2025SponsorVedanta Biosciences, Inc.Ulcerative ColitisColitis, Ulcerative